Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Q3 Results as LYMPHIR Demand Builds

• Citius Pharmaceuticals (NASDAQ: CTXR) reported a loss per share that was slightly smaller than the analyst consensus estimate.
• Quarterly revenue fell short of market expectations, although institutional demand for LYMPHIR continued to expand following its commercial launch.
• The company remains unprofitable and had negative working capital at the end of the quarter, despite holding approximately $17 million in cash.

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a biopharmaceutical company developing and commercializing therapeutic products. Its majority-owned subsidiary, Citius Oncology, Inc. (NASDAQ: CTOR), is responsible for commercializing LYMPHIR, a treatment for certain patients with relapsed or refractory cutaneous T-cell lymphoma.

On August 14, 2026, Citius Pharmaceuticals reported financial results for its fiscal third quarter ended June 30, 2026. The company recorded a GAAP loss of $0.34 per share, slightly better than the consensus estimate for a loss of $0.36 per share. It also improved from a loss of $0.80 per share in the corresponding quarter of fiscal 2025.

Citius generated $1.49 million in revenue during the quarter, compared with no revenue in the prior-year period. The result was below the reported analyst estimate of $5.46 million. For the first nine months of fiscal 2026, the company generated $7.11 million in revenue, primarily from commercial sales of LYMPHIR, which began in December 2025. Although revenue increased from zero on a year-over-year basis, it declined sequentially from approximately $1.7 million in the quarter ended March 31, 2026. 

Underlying institutional demand nevertheless showed improvement. Institutional vial orders increased 31% sequentially, from 708 vials in the quarter ended March 31 to 926 vials in the quarter ended June 30. By the end of the quarter, 44 institutions had prescribed and ordered LYMPHIR, including academic oncology centers, National Comprehensive Cancer Network institutions, and community infusion centers. 

The distinction between vial demand and reported revenue is important. Citius Oncology recognizes revenue when orders placed by wholesalers are fulfilled, while the 926-vial figure represents orders placed by prescribing institutions with wholesalers. Consequently, increased institutional demand may not appear as recognized revenue in the same reporting period.

As of June 30, 2026, the company had approximately $17.0 million in cash and cash equivalents, $43.3 million in current assets, and $51.6 million in current liabilities. These figures produce a current ratio of approximately 0.84 and negative working capital of about $8.3 million. Although the company’s debt-to-equity ratio was relatively low, this metric alone does not demonstrate strong financial health. Citius stated that it would need substantial additional financing to meet its obligations and support continued operations.